DelveInsight’s “Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Nephrotic Syndrome Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Nephrotic Syndrome Market Size
Key Takeaways from the Nephrotic Syndrome Market Report
- In January 2025:- Hoffmann-La Roche- A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome. This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
- As per DelveInsight’s estimations, the total Nephrotic Syndrome diagnosed prevalent cases in the 7MM were approximately 786k in 2022 and are projected to increase during the forecast period.
- The overall count of individuals diagnosed with Nephrotic Syndrome in the United States was approximately 268k in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020–2034).
- Among the 7MM, the US accounted for nearly 214k cases of Primary Glomerulonephropathies, and 54k cases of Secondary Glomerulonephropathies. These cases are expected to increase during the forecast period (2023–2034).
- Among EU4 and the UK, Germany had the highest Nephrotic Syndrome diagnosed prevalent population, with about 98k cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
- In Japan, there were around 151k Nephrotic Syndrome diagnosed prevalent cases in 2022. These cases are expected to decrease by 2032.
- The leading Nephrotic Syndrome Companies such as Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, Inc., AstraZeneca, and others.
- Promising Nephrotic Syndrome Therapies such as Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus, and others.
Stay ahead in the competitive landscape of the Nephrotic Syndrome Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Nephrotic Syndrome Treatment Market Size
Nephrotic Syndrome Epidemiology Segmentation in the 7MM
- Total Nephrotic Syndrome Diagnosed Prevalent Cases
- Nephrotic Syndrome Type-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Nephrotic Syndrome epidemiology trends @ Nephrotic Syndrome Prevalence
Nephrotic Syndrome Emerging Drugs
- Atacicept: Vera Therapeutics
Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.
- Atrasentan: Chinook Therapeutics/ Novartis
Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.
Nephrotic Syndrome Market Outlook
Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications of Nephrotic Syndrome. The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications of nephrotic syndrome.
Discover the future of Nephrotic Syndrome treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Nephrotic Syndrome Market Drivers and Barriers
Nephrotic Syndrome Companies
Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, Inc., AstraZeneca, and others
Scope of the Nephrotic Syndrome Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Nephrotic Syndrome Companies- Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, Inc., AstraZeneca, and others
- Nephrotic Syndrome Therapies- Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus, and others.
- Nephrotic Syndrome Therapeutic Assessment: Nephrotic Syndrome current marketed and Nephrotic Syndrome emerging therapies
- Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome market drivers and Nephrotic Syndrome market barriers
- Nephrotic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Nephrotic Syndrome Market Access and Reimbursement
Explore the dynamics of the Nephrotic Syndrome Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Nephrotic Syndrome Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Report Introduction
3. Nephrotic Syndrome Market Overview at a Glance
4. Epidemiology and Market Methodology of Nephrotic Syndrome
5. Executive Summary of Nephrotic Syndrome
6. Key Events
7. Nephrotic Syndrome: Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Therapies
12. Nephrotic Syndrome: Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market